click below
click below
Normal Size Small Size show me how
Cell Receptors
Chemistry of recoptor binding, modulators, agonist and antagonists
| Question | Answer |
|---|---|
| Most receptors are located in... | the cell membrane |
| Receptors are activated by... | Chemical messengers |
| Chemical messengers include _____ and ______ | neurotransmitters and hormones |
| Binding of messenger to receptor results in _______ _______ | Signal transduction |
| Drug that mimics natural messenger is an _____ | agonist |
| Agonist should bind and leave quickly or slowly? | quickly |
| Drug that blocks natural messenger is an _____ | antagonist |
| Antagonists alter induced fit due to _____ and/or _____ binding groups | stronger and/or more binding groups |
| Agonist must have correct ____ , ______ and ____ _____ in order to work | correct shape , positioning and binding groups |
| Enantiomers usually have ______ biological properties | different |
| Agonists usually have _____ of interactions as natural messenger | same # |
| Groups that block access to binding site are called ______ or ______ | steric blocks or steric shields |
| Agents which bind to allosteric binding site rather than the messenger binding site | allosteric modulators |
| Allosteric modulators _______ receptor activity | enhance |
| Ex. of Allosteric modulator | benzodiazepines |
| Benzodiazepines target allosteric site of | GABAa receptor |
| Reversible antagonist binds _____ to receptor and produces different ____ ___ | reversibly , induced fit |
| Does antagonist undergo rxn with receptor? | no rxn |
| Level of antagonism depends on _____ of binding and _______ | strength and [antagonist] |
| For reversible antagonist: increasing [messenger].... | lowers antagonism |
| Irreversible antagonists bind _____ to receptor by form ______ bonds | irreversibly , covalent |
| For irreversible antagonists: increasing [messenger]... | does not reverse antagonism |
| Allosteric antagonist bind ______ to _______ site of receptor | reversibly , allosteric |
| Alloseric antagonist work by.... | altering shape of receptor to block messenger action |
| For Allosteric antagonists: increasing [messenger]... | does not reverse antagonism |
| How does Antagonism by Umbrella effect work? | Antagonist binds to neighboring binding site and overlaps/covers messenger binding site |
| ______ ______ binds but does not produce maximum effect | Partial agonist |
| Partial agonists act as _____ to one receptor subtype and ______ to different subtype | agonist , antagonist |
| Define Inherent activity | any activity present in the absence of a chemical messenger |
| Inverse agonist blocks ______ ______ of receptor | inherent activity |
| Inverse agonist create equilibrium between ______ activity and _______ | inherent activity and inactivity |
| Adding agonist pushed receptor toward _____ form | active |
| Adding antagonist pushes receptor toward ____ form | inactive |
| Adding partial agonist pushes receptor toward ______ between forms | equilibrium |
| Receptors become ____ after long-term exposure to agonist | desensitized |
| Prolonged binding of agonist leads to ______ of receptor | phosphorylation |
| Phosphorylation _______ receptor until agonist leaves | deactivates |
| Receptors become ______ after long-term exposure to antagonist | sensitized |
| To compensate for antagonist-blocked receptors, cell.... | synthesizes new receptors |
| Synthesis of new receptors makes cell more sensitive to _______ | natural messenger |
| Long-term exposure to agonist can lead to ______ and ______ | tolerance and dependence |
| Tolerance results in need to.... | increase dosage of antagonist |
| Dependence results from ______ symptoms when antagonist is taken away | withdrawal |
| Estradiol binding to estrogen receptor results in _______ and exposure of _____ | dimerization , AF-2 regions |
| _______ binds to AF-2 regions of estrogen receptor in order to activate response | Coactivator |
| Raloxifene is an estrogen receptor ______ and ______ agent | antagonist and anti-cancer |
| Raloxifene works by preventing ______ so _____ regions are not exposed and coactivator doesn't bind | dimerization , AF-2 |
| Tamoxifen is an estrogen receptor ______ | antagonist |